A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Clinical trial NCT06232707 · WITHDRAWN
Trial details
- NCT number
- NCT06232707
- Sponsor
- Celgene
- Status
- WITHDRAWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-03
- Primary completion
- 2025-11-16
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.